Treatment of women affected with polycystic ovary syndrome
US12208130B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Mar 14, 2018 |
| Grant date | Jan 28, 2025 |
| Priority date | — |
| Expiry date | Jul 16, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P15/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the field of therapeutic treatment of polycystic ovary syndrome (PCOS). Polycystic ovary syndrome, PCOS, is the most common female reproductive disorder against which no therapeutic solution is available, beyond changes in the lifestyle. The inventors have now shown by using in vivo preclinical models, that individuals affected with PCOS have an abnormal elevated production of GnRH and that this elevated production of GnRH was transmitted to their offspring that also develop PCOS. Further, by examining AMH levels in a cohort of pregnant PCOS and control women, the inventors have found that AMH concentrations are significantly higher in PCOS women as compared to healthy women during the second trimester of gestation. These unexpected findings has allowed conceiving both prevention and treatment therapeutic strategies based on the administration of GnRH antagonists. Especially, the present invention relates to a gonadotropin-releasing hormone (GnRH) antagonist for its use in a woman affected with polycystic ovary syndrome (PCOS) for preventing the occurrence of PCOS in the offspring of the said woman. Even more interestingly, the present invention rel…
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.